Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trialsLANCET RHEUMATOLOGYIF16.42024-04-016PRE
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseasesJOURNAL OF INTERNAL MEDICINEIF9.22023-02-266OA
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized MedicineBIODRUGSIF6.92022-10-3122OAAI
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trialJOURNAL OF INTERNAL MEDICINEIF9.22022-04-2618OA
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial英夫利昔单抗维持治疗期间治疗药物监测与标准治疗对免疫介导的炎性疾病患者疾病控制的影响随机临床试验JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552021-12-21102OA
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical TrialJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552021-05-04100OA